TY - JOUR
T1 - Retrospective Analysis of Taxane-Based Therapy in Small Bowel Adenocarcinoma
AU - Aldrich, Jeffrey D.
AU - Raghav, Kanwal Pratap Singh
AU - Varadhachary, Gauri R.
AU - Wolff, Robert A.
AU - Overman, Michael J.
N1 - Publisher Copyright:
© AlphaMed Press 2018
PY - 2019/6
Y1 - 2019/6
N2 - Currently, treatment of small bowel adenocarcinoma (SBA) mirrors that of colorectal cancer (CRC). Recent genomic data have demonstrated SBA to be a genetically unique entity, suggesting that therapies not traditionally utilized in CRC should be explored. In order to further characterize the activity of taxanes in this rare cancer, we completed a single-center retrospective study. Twenty patients were found to have been treated with taxane-based regimens (monotherapy in 3, combination therapy in 17). Median time to progression was 3.8 months (95% confidence interval [CI] 2.9–4.6), and median overall survival was 10.7 months (95% CI: 3.1–18.3). The results of this study demonstrate clinical activity from taxane-based therapy in advanced SBA and support further clinical trial investigation.
AB - Currently, treatment of small bowel adenocarcinoma (SBA) mirrors that of colorectal cancer (CRC). Recent genomic data have demonstrated SBA to be a genetically unique entity, suggesting that therapies not traditionally utilized in CRC should be explored. In order to further characterize the activity of taxanes in this rare cancer, we completed a single-center retrospective study. Twenty patients were found to have been treated with taxane-based regimens (monotherapy in 3, combination therapy in 17). Median time to progression was 3.8 months (95% confidence interval [CI] 2.9–4.6), and median overall survival was 10.7 months (95% CI: 3.1–18.3). The results of this study demonstrate clinical activity from taxane-based therapy in advanced SBA and support further clinical trial investigation.
UR - http://www.scopus.com/inward/record.url?scp=85059265216&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059265216&partnerID=8YFLogxK
U2 - 10.1634/theoncologist.2018-0573
DO - 10.1634/theoncologist.2018-0573
M3 - Article
C2 - 30598498
AN - SCOPUS:85059265216
SN - 1083-7159
VL - 24
SP - e384-e386
JO - Oncologist
JF - Oncologist
IS - 6
ER -